Pharma BD Deal Intelligence
AbbVie and Calico Life Sciences announced the second extension of their 2014 aging and age-related disease collaboration on July 27, 2021, with each partner committing an additional ~$500M (~$1B incremental; ~$3.5B cumulative alliance value). The pipeline spanned 20+ early-stage programs in immuno-oncology and neurodegeneration, with three in clinical development at the time, anchored by the PTPN2/N1 inhibitor osunprotafib (ABBV-CLS-484) in oncology and the eIF2B activator fosigotifator (ABBV-CLS-7262) in neurodegeneration. OUTCOME: The collaboration ended in November 2025 (reported Nov 12-13). AbbVie wound down the 11-year alliance and laid off ~100 chemists after fosigotifator failed to significantly slow disease progression in the HEALEY ALS Platform Trial (reported Jan 2025) and AbbVie pivoted away from small-molecule discovery toward biologics and genetic medicines. Over its life the alliance produced limited clinical success; the anti-PAPP-A antibody ABBV-CLS-628 (ADPKD; FDA fast-track Oct 2025) and the osunprotafib oncology Phase 1 (NCT04777994) continued under AbbVie at the time of the wind-down.